Com Products 
a Unit of CPC North America 
Moffett Technical Center, Box 345, Summit-Argo, IL 60501, (312) 458-2000 
January 10, 1983 
Dr. William J. Gartland, Jr. 
Director, Office of Recombinant DNA Activities 
National Institutes of Health 
Building 31, Room 4A52 
Bethesda, Maryland 20205 
Dear Dr. Gartland: 
The following is a summary of the comments by members of the Corn 
Products Company IBC regarding the attached Office of Recombinant DNA 
Activities questionnaire concerning the NIH Guidelines. 
#1 . What are the problems with the revised guidelines? 
There should be a mechanism by which the IBC can approve the 
deliberate release into the environment of organisms contain- 
ing recombinant DNA (section III-A-2) when the organisms are 
non-pathogenic and the recombinant DNA contained within the 
organisms is not derived from pathogens. 
#6. How frequently does your IBC meet? 
IBC meetings are held every 6-8 months or when needed. 
#7. Does your IBC have other responsibilities at your institution? 
Is it a general biosafety committee? If not, is it because of 
the way in which the NIH Guidelines are written or is it 
because your institution has chosen to function this way? 
The Corn Products Company IBC reviews and regulates rDNA 
experimentation and does not function as a general biosafety 
committee. Corn Products Company established the IBC in order 
to voluntarily comply with the NIH Guidelines. 
epc 
International 
[ 567 ] 
